National Antiviral Service Cymru (NAVS)
The National Antiviral Service Cymru (NAVS) is coordinating the supply of treatments for COVID-19 for the most vulnerable individuals across Wales who have not been admitted to hospital.
COVID-19 treatment for people in the community
Treatment for COVID-19 is available for people who are not in hospital but who are considered at the highest risk of becoming severely ill and being admitted to hospital. It is recommended that these treatments are started within 5 days of your symptoms starting to be of most benefit.
You can access the NAVS Self-Referral Portal here if you believe you are eligible for antiviral treatment after testing positive for COVID-19 and you are a Welsh resident.
Who is eligible to receive these treatments?
Treatment for COVID-19 is available for individuals who are not in hospital but who are considered at the highest risk of becoming severely ill and being admitted to hospital. This will include some people, but not everyone who was advised to shield during the pandemic.
These individuals will usually be contacted within 48 hours of a positive PCR test or Lateral Flow Test (LFT) that has been reported.
The highest risk group includes people who have:
- Down’s syndrome
- a rare condition affecting the brain or nerves (including multiple sclerosis, motor neurone disease, Huntington’s disease or myasthenia gravis)
- sickle cell disease
- certain types of cancer
- HIV or AIDS
- a severe liver condition (such as cirrhosis)
- chronic kidney disease (CKD) stage 4 or 5
- had an organ transplant
- certain autoimmune or inflammatory conditions (such as rheumatoid arthritis or inflammatory bowel disease)
- a condition or treatment that makes you more likely to get infections
- had certain types of chemotherapy in the last 12 months
- had radiotherapy in the last 12 months
Visit the page Get tested for coronavirus (COVID-19) | GOV.WALES for information on how to get tested.
Healthcare professionals can access the online referral portal via your Trust intranet page.